Literature DB >> 26904569

Enhancing radiotherapy: breaking free from undue zeal for the existent, and utter contempt for the prospective.

Swaroop Revannasiddaiah1.   

Abstract

Year:  2016        PMID： 26904569      PMCID： PMC4740005          DOI： 10.3978/j.issn.2305-5839.2016.01.17

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  3 in total

1.  Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

Authors:  K Kian Ang; Qiang Zhang; David I Rosenthal; Phuc Felix Nguyen-Tan; Eric J Sherman; Randal S Weber; James M Galvin; James A Bonner; Jonathan Harris; Adel K El-Naggar; Maura L Gillison; Richard C Jordan; Andre A Konski; Wade L Thorstad; Andy Trotti; Jonathan J Beitler; Adam S Garden; William J Spanos; Sue S Yom; Rita S Axelrod
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

Review 2.  The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective.

Authors:  Ozlem U Ataman; Sally J Sambrook; Chris Wilks; Andrew Lloyd; Amanda E Taylor; Stephen R Wedge
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-07-20       Impact factor: 7.038

Review 3.  Temozolomide for high grade glioma.

Authors:  Michael G Hart; Ruth Garside; Gabriel Rogers; Ken Stein; Robin Grant
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.